mirage

Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant

ABACUS/Manakin Repository

Show simple item record

dc.contributor.author Berenguer, Juan
dc.contributor.author Jarrín, Inmaculada
dc.contributor.author Pérez-Latorre, Leire
dc.contributor.author Hontañón, Víctor
dc.contributor.author Vivancos, María J.
dc.contributor.author Navarro, Jordi
dc.contributor.author Téllez, María J.
dc.contributor.author Guardiolo, Josep M.
dc.contributor.author Iribarren, J. A.
dc.contributor.author Hernando Jeréz, María Asunción
dc.contributor.author GeSIDA 8514 Study Group
dc.date.accessioned 2018-02-21T16:45:58Z
dc.date.available 2018-02-21T16:45:58Z
dc.date.issued 2018
dc.identifier.citation Berenguer, J., Jarrín, I., Pérez-Latorre, L., Hontañón, V., Vivancos, M. J., Navarro, J., ... & Márquez, M. (2018). Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant. Open Forum Infectious Diseases, 5(1). DOI: 10.1093/ofid/ofx258 spa
dc.identifier.issn 2328-8957
dc.identifier.uri http://hdl.handle.net/11268/7072
dc.description.abstract Background. We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015. Methods. The study was performed in 43 centers during October–November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility. Results. The reference population and the sample size were 38 904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy. Conclusions. Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals. spa
dc.description.sponsorship Fundación SEIMC-GESIDA, Madrid, Spain spa
dc.language.iso eng spa
dc.title Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant spa
dc.type article spa
dc.description.impact 3.240 JCR (2017) Q2, 31/88 Infectious Diseases spa
dc.identifier.doi 10.1093/ofid/ofx258
dc.rights.accessRights openAccess spa
dc.subject.uem Epidemiología spa
dc.subject.uem Hepatitis spa
dc.subject.unesco Epidemiología spa
dc.subject.unesco Enfermedad spa
dc.description.filiation UEM spa
dc.relation.publisherversion https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767960/ pdf/ofx258.pdf spa
dc.peerreviewed Si spa


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record